



## MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

September 3, 2024

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, Chief Executive Officer, will participate in a fireside chat and investor one-on-ones at the upcoming H.C. Wainwright 26<sup>th</sup> Annual Global Investment Conference on September 9-11<sup>th</sup>. The fireside chat will take place at 7:00 a.m. ET on Monday, September 9<sup>th</sup>.

To access this event, please register at <https://journey.ct.events/view/ad5300ce-fb6d-41fc-a276-ec783460f6d9>. Following the event, a replay of the fireside chat will be posted to MiNK's website at <https://investor.minktherapeutics.com/events-and-presentations>.

### About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit <https://minktherapeutics.com/> or @MiNK\_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.

### Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agent-797 and iNKT cells the mechanism of action, potency and safety, interim or top-line data, including statements regarding clinical data of agent-797, the anticipated benefits of agent-797 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

### Investor Contact

917-362-1370

[investor@minktherapeutics.com](mailto:investor@minktherapeutics.com)

### Media Contact

781-674-4428

[communications@minktherapeutics.com](mailto:communications@minktherapeutics.com)



Source: MiNK Therapeutics